Changes in glycerophospholipid profile in experimental nephrotic syndrome

Metabolism: Clinical and Experimental

Volumn 45, Issue 7, 1996, Pages 822-826

  Mimura, Keiji ^a   Zhao, Biren ^a   Muguruma, Kouei ^a   Frenkel, Rene A ^a   Johnston, John M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; GLYCEROPHOSPHOLIPID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PLASMALOGEN; PUROMYCIN AMINONUCLEOSIDE; THROMBOCYTE ACTIVATING FACTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERLIPIDEMIA; KIDNEY MICROSOME; LIPID ANALYSIS; LIVER MICROSOME; LIVER MITOCHONDRION; MALE; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RAT;

EID: 0029952191     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90153-5     Document Type: Article

References (38)

1. Kees-Folts D, Diamond JR: Relationship between hyperlipidemia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome. Am J Nephrol 13:365-375, 1993
2. Epstein AA: The nature and treatment of chronic parenchymatous nephritis (nephrosis). JAMA 69:444-447, 1917
3. Moorhead JF, Chan MK, El-Nahas M, et al: Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 2:1309-1312, 1982
4. Frenkel RA, Johnston JM: Metabolic conversion of platelet-activating factor into ethanolamine plasmalogen in an amnion-derived cell line. J Biol Chem 267:19186-19191, 1992
5. Daniel LW, Waite M, Wykle RL: A novel mechanism of diglyceride formation. J Biol Chem 261:9128-9132, 1986
6. Baker RC: 1-O-alk-1′enyl-2-acyl-GPE (ethanolamine plasmalogen) is the end ether lipid metabolite of platelet activating factor. FASEB J 3:1377A, 1988 (abstr)
7. Gherardi E, Vecchia L, Calandra S: Experimental nephrotic syndrome in the rat induced by puromycin aminonucleoside. Plasma and urinary lipoproteins. Exp Mol Pathol 32:128-142, 1980
8. Mimura K: Experimental studies on urinary phospholipid excretion in puromycin aminonucleoside-induced nephrotic rats. J Wakayama Med Soc 35:505-516, 1984
9. Remuzzi G: Eicosanoids and platelet activating factor as possible mediators of injury in experimental nephropathies. Adv Exp Med Biol 259:221-247, 1989
10. Mimura K, Yukawa S, Maeda T, et al: Selective urinary excretion of phosphatidylethanolamine in patients with chronic glomerular diseases. Metabolism 33:882-890, 1984
11. Lowry OH, Rosebrough NJ, Farr AL, et al: Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275, 1951
12. Bligh EC, Dyer WL: A rapid method for total lipid extraction and purification. Can J Biochem Physiol 37:911-917, 1959
13. Rouser G, Siakotos AN, Fleischer S: Quantitative analysis of phospholipids by thin-layer chromatography and phosphorus analysis of spots. Lipids 1:85-86, 1966
14. Renkonen O: The analysis of individual molecular species of polar lipids. Adv Lipid Res 5:329-351, 1967
15. Doumas BT, Watson WA, Giggs HG: Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 31:87-96, 1971
16. Miwa M, Miyake T, Yamanaka T, et al: Characteristics of serum platelet-activating factor (PAF) acetylhydrolase: Correlation between deficiency of serum PAF-AH on respiratory symptoms in asthmatic children. J Clin Invest 82:1983-1991, 1988
17. Miyaura S, Eguchi H, Johnston JM: Effect of a cigarette smoke extract on the metabolism of the proinflammatory autacoid, platelet-activating factor. Circ Res 70:341-347, 1992
18. Elstad MR, Stafforini DM, McIntyre TM, et al: Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor. J Biol Chem 264:8467-8470, 1989
19. Horrocks LA: Ether-containing mammalian and avian lipids, in Snyder F (ed): Ether Lipids, Chemistry and Biology. New York, NY, Academic, 1972, pp 177-272
20. Gross RW: High plasmalogen and arachidonic acid content of canine myocardial sarcolemma: A fast atom bombardment mass spectroscopic and gas chromatography-mass spectroscopic characterization. Biochemistry 23:158-165, 1984
21. Ford DA, Gross RW: Plasmenylethanolamine is the major storage depot for arachidonic acid in rabbit vascular smooth muscle and is rapidly hydrolyzed after angiotensin II stimulation. Proc Natl Acad Sci USA 86:3479-3483, 1989
22. Zoeller RA, Morand OH, Raetz CRH: A possible role for plasmalogens in protecting animal cells against photosensitized killing. J Biol Chem 263:11590-11596, 1988
23. Vance JE: Lipoproteins secreted by cultured rat hepatocytes contain the antioxidant 1-aik-1-enyl-2-acylglycerophosphoethanol-amine. Biochim Biophys Acta 1045:128-134, 1990
24. Schrakamp G, Roosenboom CFP, Schutgens RBH, et al: Alkyl dihydroxyacetone phosphate synthase in human flbroblasts and its deficiency in Zellweger syndrome. J Lipid Res 26:867-873, 1985
25. Datta NS, Wilson GN, Hajra AK: Deficiency of enzymes catalyzing the biosynthesis of glycerol-ether lipids in Zellweger syndrome. A new category of metabolic disease involving the absence of peroxisomes. N Engl J Med 311:1080-1983, 1984
26. Borst P: Animal peroxisomes (microbodies), lipid biosynthesis and the Zellweger syndrome. Trends Biochem Sci 8:269-272, 1983
27. 5 in plasmalogen biosynthesis. J Biol Chem 249:2661-2662, 1974
28. Caramelo C, Fernandez-Gallardo S, Marin-Cao D, et al: Presence of platelet-activating factor in blood from humans and experimental animals. Its absence in anephric individuals. Biochem Biophys Res Commun 120:789-796, 1984
29. Pirotzky E, Egido J, Colliez P, et al: Involvement of platelet-activating factor in renal processes. Adv Lipid Res 23:277-293, 1989
30. Lee T-C, Malone B, Woodard D, et al: Renal necrosis and the involvement of a single enzyme of the de novo pathway for the biosynthesis of platelet-activating factor in the rat kidney inner medulla. Biochem Biophys Res Commun 163:1002-1005, 1989
31. Lianos EA, Zanglis A: Glomerular platelet-activating factor levels and origin in experimental glomerulonephritis. Kidney Int 37:736-740, 1990
32. 2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: Evidence from biochemical measurements and inhibitor trials. J Lab Clin Med 113:549-560, 1989
33. Muirhead EE, Jones F, Stirmann JA: Antihypertensive property in renoprival hypertension of extract from renal medulla. J Lab Clin Med 56:167-180, 1960
34. Blank ML, Snyder F, Byers LW, et al: Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commun 90:1194-1200, 1979
35. McGowan HMR, Vandongen R, Kelly LD, et al: Increased levels of platelet-activating factor (1-O-alkyl-2-acetylglycero-phosphocholine) in blood after reversal of renal clip hypertension in the rat. Clin Sci 74:393-396, 1988
36. Yasuda K, Eguchi H, Narahara H, et al: Platelet-activating factor: Its regulation in parturition in eicosanoids and other bioactive lipids, in Nigam S, Honn KV, Marnett LJ, et al (eds): Cancer, Inflammation and Radiation Injury. Norwell, MA, Kluwer Academic, 1993, pp 727-730
37. Toyoshima K, Narahara H, Furukawa M, et al: Platelet-activating factor. Role in fetal lung development and relationship to normal and premature labor. Clin Perinatol 22:263-280, 1995
38. Satoh K, Imaizumi T, Kawamura Y, et al: Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2. J Clin Invest 87:476-481, 1991